Madrigal Pharmaceuticals, Inc.
MDGL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001157601
In the last 90 days, Madrigal Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 3 sales; 416 institutions reported holding it in 13F filings for Q2 2026, worth $12.7B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $10.1B
- Insider buysLast 90 days, $35.0M in total
- 1
- Insider sellsLast 90 days, $7.01M in total
- 3
- 13F holdersQ2 2026, +38 vs. previous quarter
- 416
- 13F valueReported value at the end of Q2 2026
- $12.7B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $958.4M
- +432.1% year over year
- Net income, FY2025
- -$288.3M
- No comparable prior period
- Free cash flow, FY2025
- -$190.0M
- No comparable prior period
- Revenue, Q3 FY2026
- $431.3M
- +50.1% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $288.3M (30.1% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 2.14M
- Shares sold short
- Change
- −58.1K
- −2.7% vs. previous
- Days to cover
- 7.64
- At average daily volume
Superinvestors holding MDGL, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding MDGL at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Madrigal Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 6, 2026 (view filing)5:30 PM ET | Nov 4-6 | 2 days | Baker Julian and 5 othersDirector | PPurchase | +91.8K | $381.49 | +$35.0M | +4.7%2.04M after | 5 lots |
| Nov 6, 2026 (view filing)4:36 PM ET | Nov 6 | Same day | Kelley Shannon TGeneral Counsel | SSale | −1.08K | $400.00 | −$430.8K | −9.4%10.4K after | 10b5-1 |
| Sep 11, 2026 (view filing)4:57 PM ET | Sep 9-11 | 2 days | Sibold William JohnPresident and CEO | SSale | −11.6K | $538.65 | −$6.24M | −5.5%197.7K after | 24 lots10b5-1 |
| Aug 20, 2026 (view filing)4:20 PM ET | Aug 17 | 3 daysLate | Kelley Shannon TGeneral Counsel | SSale | −664 | $514.97 | −$341.9K | −5.5%11.5K after | |
| Jul 20, 2026 (view filing)9:16 PM ET | Jul 20 | Same day | Sibold William JohnPresident and CEO | SSale | −2.50K | $547.30 | −$1.37M | −1.2%209.3K after | 10 lots |
| Jun 1, 2026 (view filing) | Jun 1 | Same day | Soergel DavidChief Medical Officer | SSale | −1.04K | $495.74 | −$516.6K | −9.4%10.0K after | 10b5-1 |
| May 22, 2026 (view filing) | May 22 | Same day | Levy Richard SDirector | SSale | −5.68K | $515.44 | −$2.93M | −20.5%22.0K after | 12 lots10b5-1 |
| May 18, 2026 (view filing) | May 18 | Same day | Soergel DavidChief Medical Officer | SSale | −844 | $515.90 | −$435.4K | −7.1%11.1K after | |
| Mar 6, 2026 (view filing) | Mar 6 | Same day | Dier MardiEVP and CFO | SSale | −1.98K | $430.87 | −$854.0K | −13.7%12.5K after | 12 lots10b5-1 |
| Mar 6, 2026 (view filing) | Mar 6 | Same day | Sibold William JohnPresident and CEO | SSale | −1.66K | $431.94 | −$718.3K | −1.0%161.8K after |
Top 10 13F holders, Q2 2026
See all 416 holdersThe largest institutional positions in Madrigal Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 2,143,131 | $1.15B | 5.77% | +1,430+0.1% | Added |
| RTW Investments, LP | 1,993,687 | $1.07B | 9.14% | 00.0% | Unchanged |
| Jupiter Topco LLC | 1,936,099 | $1.04B | 0.42% | +1,936,099 | New |
| Avoro Capital Advisors LLC | 1,833,333 | $984.4M | 8.84% | +15,152+0.8% | Added |
| Paulson & Co. Inc. | 1,340,020 | $719.5M | 27.94% | −52,168−3.7% | Reduced |
| BlackRock, Inc. | 1,200,770 | $644.8M | 0.01% | −359,195−23.0% | Reduced |
| Vanguard Capital Management LLC | 835,668 | $448.7M | 0.01% | +8,524+1.0% | Added |
| Wellington Management Group LLP | 825,714 | $443.4M | 0.08% | +130,756+18.8% | Added |
| Vanguard Portfolio Management LLC | 781,731 | $419.8M | 0.02% | −59,414−7.1% | Reduced |
| State Street Corp | 527,057 | $283.0M | 0.01% | −82,468−13.5% | Reduced |
Holders of 5% or more of MDGL
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Madrigal Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 13D/A | 9.99%2.33M shares | – | Feb 16, 20218 filings | Nov 6, 2026 | SEC |
| Janus Henderson Group PLC | 13G/A | 8.80%2.02M shares | +1.80 ppfrom 7.00% | Sep 8, 202310 filings | May 15, 2026 | SEC |
| Taub Rebecca | 13D/A | 7.80%1.81M shares | – | Dec 12, 20251 filing | Dec 12, 2025 | SEC |
| Friedman Paul A | 13D/A | 7.80%1.81M shares | – | Dec 12, 20251 filing | Dec 12, 2025 | SEC |
| Paulson & Co. Inc. | 13G/A | 6.10%1.39M shares | −1.40 ppfrom 7.50% | Nov 13, 20235 filings | May 15, 2026 | SEC |
Politician trades
All politician trades in MDGL1 member of Congress reported 1 trade in Madrigal Pharmaceuticals, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| May 19, 2023 |  Daniel S. Goldman House · NY | Sell | $1K-$15K |
House · NY · May 19, 2023
Sell$1K-$15K